KR20070059151A - 하부요로 폐색 질환에 따른 축뇨장해의 예방 및/또는치료제 - Google Patents
하부요로 폐색 질환에 따른 축뇨장해의 예방 및/또는치료제 Download PDFInfo
- Publication number
- KR20070059151A KR20070059151A KR1020077008737A KR20077008737A KR20070059151A KR 20070059151 A KR20070059151 A KR 20070059151A KR 1020077008737 A KR1020077008737 A KR 1020077008737A KR 20077008737 A KR20077008737 A KR 20077008737A KR 20070059151 A KR20070059151 A KR 20070059151A
- Authority
- KR
- South Korea
- Prior art keywords
- group
- urinary tract
- therapeutic agent
- prophylactic
- quot
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Claims (6)
- 하기 일반식 (I)로 표시되는 인돌린 유도체 또는 그 약리학적으로 허용되는 염을 함유하는 것을 특징으로 하는 하부요로 폐색 질환에 따른 축뇨장해의 예방 및/또는 치료제.(식 중, R은 치환기로서 1개 내지 그 이상의 할로겐 원자, 수산기, 저급 알콕시기, 카르복시기, 저급 알콕시카르보닐기, 시클로알킬기 또는 아릴기를 가지고 있어도 되고 불포화 결합을 가지기도 하는 지방족 아실기, 히드록시알킬기, 지방족 아실옥시알킬기, 치환기로서 저급 알콕시기, 카르복시기, 저급 알콕시카르보닐기, 아릴 치환 저급 알콕시카르보닐기, 카르바모일기, 모노 또는 디알킬 치환 카르보닐기 또는 시아노기를 갖는 저급 알킬기, 치환기로서 1개 내지 그 이상의 할로겐 원자를 가지고 있어도 되는 방향족 아실기, 푸로일기 또는 피리딜카르보닐기이고, R1은 시아노기 또는 카르바모일기이고, R2는 치환기로서 1개 내지 그 이상의 할로겐 원자, 시아노기 또는 아릴기를 가지고 있어도 되는 저급 알킬기를 나타낸다.)
- 제 1 항에 있어서, 인돌린 유도체가 실로도신인 것을 특징으로 하는 하부요 로 폐색 질환에 따른 축뇨장해의 예방 및/또는 치료제.
- 제 1 항 또는 제 2 항에 있어서, 하부요로 폐색 질환이 전립선 비대증인 것을 특징으로 하는 하부요로 폐색 질환에 따른 축뇨장해의 예방 및/또는 치료제.
- 제 1 항 내지 제 3 항에 있어서, 국제 전립선 증상 스코어에서 투여 전에 있어서의「2시간 이내의 배뇨」및「요의절박감」의 합계 스코어가 6 이상인 환자에게 투여하는 것을 특징으로 하는 하부요로 폐색 질환에 따른 축뇨장해의 예방 및/또는 치료제.
- 제 1 항 내지 제 4 항 중 어느 한 항에 있어서, 일반식 (I)로 표시되는 인돌린 유도체 또는 그 약리학적으로 허용되는 염의 1회 투여량이 2∼16mg인 것을 특징으로 하는 하부요로 폐색 질환에 따른 축뇨장해의 예방 및/또는 치료제.
- 제 1 항 내지 제 5 항 중 어느 한 항에 있어서, 축뇨장해에 사용할 수 있는 다른 약제를 더 함유하는 것을 특징으로 하는 하부요로 폐색 질환에 따른 축뇨장해의 예방 및/또는 치료제.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JPJP-P-2004-00292731 | 2004-10-05 | ||
JP2004292731 | 2004-10-05 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20070059151A true KR20070059151A (ko) | 2007-06-11 |
KR100965205B1 KR100965205B1 (ko) | 2010-06-24 |
Family
ID=36142684
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020077008737A KR100965205B1 (ko) | 2004-10-05 | 2005-10-04 | 하부요로 폐색 질환에 따른 축뇨장해의 예방 및/또는치료제 |
Country Status (8)
Country | Link |
---|---|
US (2) | US20090227651A1 (ko) |
EP (1) | EP1800677A4 (ko) |
JP (1) | JPWO2006038611A1 (ko) |
KR (1) | KR100965205B1 (ko) |
CN (1) | CN101027052A (ko) |
CA (1) | CA2582339C (ko) |
TW (1) | TW200621234A (ko) |
WO (1) | WO2006038611A1 (ko) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009067737A (ja) * | 2007-09-14 | 2009-04-02 | Kitasato Institute | 放射線治療後下部尿路症状の治療及び/または予防剤 |
JP6482243B2 (ja) * | 2013-11-12 | 2019-03-13 | キッセイ薬品工業株式会社 | 末梢神経障害における感覚神経障害の予防または治療用医薬組成物 |
US9460365B1 (en) * | 2015-03-24 | 2016-10-04 | Intel Corporation | Clustered palette compression |
CN104984130A (zh) * | 2015-07-16 | 2015-10-21 | 石学乾 | 一种治疗尿路梗阻的中药制剂 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU9095998A (en) * | 1997-09-22 | 1999-04-12 | Kissei Pharmaceutical Co. Ltd. | Remedies for dysuria resulting from prostatic hypertrophy |
JP4324266B2 (ja) | 1999-02-26 | 2009-09-02 | キッセイ薬品工業株式会社 | α1Aアドレナリン受容体の変異体、当該変異体を用いた測定方法及び前立腺肥大に伴う排尿困難症治療剤 |
JP2001288115A (ja) * | 2001-02-07 | 2001-10-16 | Yamanouchi Pharmaceut Co Ltd | 下部尿路症治療剤 |
UA78854C2 (en) * | 2002-09-06 | 2007-04-25 | Kissei Pharmaceutical | Crystal for an oral solid drug and oral solid drug for dysuria treatment containing the same |
EP1574215B1 (en) * | 2002-12-16 | 2015-07-15 | Kissei Pharmaceutical Co., Ltd. | Solid drug for oral use |
BRPI0404050A (pt) * | 2003-09-24 | 2005-06-14 | Bioxell Spa | Uso de um composto ou de um seu sal ou éster farmaceuticamente aceitável, formulação farmacêutica, formulação acondicionada, composto, e, método para prevenir e/ou tratar hiperplasia benigna da próstata em pacientes em necessidade de tal prevenção ou tratamento |
JP5004215B2 (ja) * | 2004-03-05 | 2012-08-22 | キッセイ薬品工業株式会社 | 神経障害に伴う過活動膀胱の予防または治療用医薬組成物 |
JP4808613B2 (ja) * | 2004-03-24 | 2011-11-02 | キッセイ薬品工業株式会社 | 頻尿または尿失禁の予防または治療用医薬 |
-
2005
- 2005-10-04 KR KR1020077008737A patent/KR100965205B1/ko active IP Right Grant
- 2005-10-04 CA CA2582339A patent/CA2582339C/en active Active
- 2005-10-04 WO PCT/JP2005/018334 patent/WO2006038611A1/ja active Application Filing
- 2005-10-04 CN CNA2005800324847A patent/CN101027052A/zh active Pending
- 2005-10-04 JP JP2006539293A patent/JPWO2006038611A1/ja active Pending
- 2005-10-04 US US11/576,678 patent/US20090227651A1/en not_active Abandoned
- 2005-10-04 EP EP05790516A patent/EP1800677A4/en not_active Withdrawn
- 2005-10-05 TW TW094134755A patent/TW200621234A/zh unknown
-
2010
- 2010-02-01 US US12/697,821 patent/US20100137399A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2582339A1 (en) | 2006-04-13 |
EP1800677A4 (en) | 2008-04-02 |
KR100965205B1 (ko) | 2010-06-24 |
US20100137399A1 (en) | 2010-06-03 |
CN101027052A (zh) | 2007-08-29 |
CA2582339C (en) | 2014-04-22 |
US20090227651A1 (en) | 2009-09-10 |
JPWO2006038611A1 (ja) | 2008-05-15 |
EP1800677A1 (en) | 2007-06-27 |
TW200621234A (en) | 2006-07-01 |
WO2006038611A1 (ja) | 2006-04-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPS61277620A (ja) | 排尿困難治療剤 | |
US20060293309A1 (en) | Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors | |
US20050131049A1 (en) | Derivatives of aryl (or heteroaryl) azolylcarbinoles for the treatment of urinary incontinence | |
US20060035923A1 (en) | Overactive bladder treating drug | |
KR100965205B1 (ko) | 하부요로 폐색 질환에 따른 축뇨장해의 예방 및/또는치료제 | |
EP1728508B1 (en) | Medicine for prevention or treatment of frequent urination or urinary incontinence | |
JP5313686B2 (ja) | 失禁治療方法 | |
CA2582045C (en) | Medicinal composition for prevention of transition to operative treatment for prostatic hypertrophy | |
EP3332779B1 (en) | Ameliorating agent for detrusor hyperactivity with impaired contractility | |
JP2005516977A (ja) | 尿失禁の処置での4−(2−フルオロフェニル)−6−メチル−2−(1−ピペラジニル)チエノ(2,3−d−ピリミジン)の使用 | |
WO2006051797A1 (ja) | 間質性膀胱炎の治療薬 | |
JP6031722B2 (ja) | 女性の排尿障害の治療剤 | |
JP6894555B1 (ja) | 排尿症状治療剤 | |
EP4176873A1 (en) | Urinary symptom therapeutic agent | |
WO2005007155A1 (ja) | 医薬組成物 | |
TW201043610A (en) | Methods of treating bladder dysfunction using netupitant | |
JP2010013441A (ja) | 過活動膀胱治療剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130329 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20140414 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20150424 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20160414 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20170512 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20180406 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20190424 Year of fee payment: 10 |